These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 347229)

  • 1. The assessment of an antiarrhythmic agent, sustained-release procainamide, with the aid of Holter monitoring.
    Bauer GE; Mitchell AS; Bates F; Hellestrand K
    Med J Aust; 1977 Nov; 2(22):733-5. PubMed ID: 347229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a new sustained release procainamide preparation: evaluation with 24-hour Holter monitoring.
    Garcia JR; Godley ML; Freedman RJ
    J La State Med Soc; 1982; 134(1):8-9. PubMed ID: 7086265
    [No Abstract]   [Full Text] [Related]  

  • 3. Experiences on a sustained-release procainamide preparation.
    Ruosteenoja R; Torsti P; Sothmann A
    Curr Ther Res Clin Exp; 1973 Oct; 15(10):707-12. PubMed ID: 4201315
    [No Abstract]   [Full Text] [Related]  

  • 4. Dosage, plasms concentration and antiarrhythmic effect of procainamide in sustained-release tablets.
    Arstila M; Katila M; Sundquist H; Anttila M; Pere E; Tikkanen R
    Acta Med Scand; 1974 Mar; 195(3):217-22. PubMed ID: 4595254
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiarrhythmic drug therapy for sporadic ventricular ectopic arrhythmias.
    Jelinek MV; Lohrbauer L; Lown B
    Circulation; 1974 Apr; 49(4):659-66. PubMed ID: 4817707
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction.
    Koch-Weser J; Klein SW; Foo-Canto LL; Kastor JA; DeSanctis RW
    N Engl J Med; 1969 Dec; 281(23):1253-60. PubMed ID: 4900236
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias.
    Hilleman DE; Patterson AJ; Mohiuddin SM; Ortmeier BG; Destache CJ
    Drug Intell Clin Pharm; 1988; 22(7-8):554-8. PubMed ID: 2458219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic therapy, ventricular premature depolarizations and sudden cardiac death: the tip of the iceberg.
    Cobb LA; Werner JA
    Circulation; 1979 May; 59(5):864-5. PubMed ID: 428097
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiarrhythmic drug therapy in survivors of prehospital cardiac arrest: comparison of effects on chronic ventricular arrhythmias and recurrent cardiac arrest.
    Myerburg RJ; Conde C; Sheps DS; Appel RA; Kiem I; Sung RJ; Castellanos A
    Circulation; 1979 May; 59(5):855-63. PubMed ID: 428096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new sustained-release tablet formulation of procainamide.
    Fremstad D; Dahl S; Jacobsen S; Lunde PK; Nådland KJ; Marthinsen AA; Waaler T; Landmark KH
    Eur J Clin Pharmacol; 1973 Dec; 6(4):251-5. PubMed ID: 4591152
    [No Abstract]   [Full Text] [Related]  

  • 11. [Oral administration of procainamide for ventricular arrhythmia. Plasma concentrations during use of tablets(Pronestyl) and a slow-release preparation (Porcainamide Durettes)].
    Bliddal J
    Ugeskr Laeger; 1976 Sep; 138(40):2425-33. PubMed ID: 968996
    [No Abstract]   [Full Text] [Related]  

  • 12. [Serum concentrations of procainamide during treatment with ordinary and sustained-release tablets].
    Henningsen P; Laursen HB; Christiansen BD; Moller J
    Ugeskr Laeger; 1976 Sep; 138(40):2433-7. PubMed ID: 968997
    [No Abstract]   [Full Text] [Related]  

  • 13. Conventional and sustained-release procainamide: update on pharmacology and clinical use.
    Anderson JL
    Clin Ther; 1985; 7(5):618-40. PubMed ID: 3902240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance therapy with a new retard tablet preparation of procainamide.
    Hansteen V; Landmark KH; Fremstad D; Dahl SG; Jacobsen S; Marthinsen AA; Waaler T; Frislid K; Lunde PK
    Am Heart J; 1976 Jul; 92(1):47-56. PubMed ID: 785987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of ventricular arrhythmias after acute myocardial infarct with procaine amide and mexiletine].
    Dolder M; Campbell RW; Talbot RG; Murray A; Prescott LE; Julian DG
    Adv Clin Pharmacol; 1978; 16():59-70. PubMed ID: 356554
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical use of sustained-release procainamide in treatment of cardiac arrhythmias.
    Michelson EL; McGeehin FC; Levin BK
    Angiology; 1988 Jul; 39(7 Pt 2):647-54. PubMed ID: 3044199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide.
    Sonnhag C; Karlsson E
    Eur J Clin Pharmacol; 1979 Jun; 15(5):311-7. PubMed ID: 378673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of procainamide and quinidine for better tolerance and additive effects for ventricular arrhythmias.
    Kim SG; Seiden SW; Matos JA; Waspe LE; Fisher JD
    Am J Cardiol; 1985 Jul; 56(1):84-8. PubMed ID: 4014046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a sustained release procainamide preparation.
    Flanagan AD
    Angiology; 1982 Feb; 33(2):71-7. PubMed ID: 7039427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agranulocytosis due to new sustained-release procainamide.
    Berger BE; Hauser DJ
    Am Heart J; 1983 Jun; 105(6):1035-6. PubMed ID: 6858823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.